So much for going public.
Less than three weeks after Carmot Therapeutics filed initial plans to go public, the fledgling biopharma, which is developing therapeutics for obesity and diabetes, chose a much more lucrative way to monetize its potential. It agreed to be acquired by Roche Holdings for as much as $3.1
